Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219284 · ClinicalTrials.gov registry record · Phase 4
Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 359
- Enrollment target
NCT00219284 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 359 participants.
The verdict
NCT00219284, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 359 participants
- Enrollment target
Study Summary
To assess motor function and quality of life (QoL) in Parkinson's disease (PD) subjects with end-of-dose wearing off, comparing immediate and delayed switch to carbidopa/levodopa and entacapone.
Interventions
- DRUG Carbidopa/levodopa/entacapone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 359 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00219284
The ClinicalTrials.gov registry entry for NCT00219284 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 359 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Carbidopa/levodopa/entacapone is the first listed.
NCT00219284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00219284 about?
NCT00219284 is a clinical study titled "Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease". To assess motor function and quality of life (QoL) in Parkinson's disease (PD) subjects with end-of-dose wearing off, comparing immediate and delayed switch to carbidopa/levodopa and entacapone.
What is the current status of trial NCT00219284?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 359 participants. The study started on 2005-01. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00219284?
The interventions under investigation include: Carbidopa/levodopa/entacapone (DRUG).
Who is sponsoring clinical trial NCT00219284?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.